Logo image
DNMT3A co-mutation in an IDH1-mutant glioblastoma
Journal article   Open access   Peer reviewed

DNMT3A co-mutation in an IDH1-mutant glioblastoma

Elena Fomchenko, E. Zeynep Erson-Omay, Amy Zhao, Ranjit S. Bindra, Anita Huttner, Robert K. Fulbright and Jennifer Moliterno
Cold Spring Harbor molecular case studies, v 5(4), 004119
01 Aug 2019
PMID: 31371348
url
https://doi.org/10.1101/mcs.a004119View
Published, Version of Record (VoR) Open

Abstract

Life Sciences & Biomedicine Medicine, Research & Experimental Research & Experimental Medicine Science & Technology
Glioblastomas are highly aggressive, infiltrative, and genetically heterogeneous primary brain tumors that arise de novo or secondarily progress over time from low-grade tumors. Along with well-established signature mutational profiles, emerging research suggests that the epigenetic tumor landscape plays an important role in gliomagenesis via transcriptional regulation, DNA methylation, and histone modifications. The pursuit of targeted therapeutic approaches, based not only on expression profiles but also on somatic mutations, is fundamental to the effort of improving survival in patients with glioblastoma. Here, we describe a missense DNMT3A p.P904S mutation in an IDH1-mutant glioblastoma. Although never previously reported in gliomas, this mutation is predicted to be pathogenic and has been reported in several other malignancies. Our report suggests that elucidating epigenetic control is important to understanding glioblastoma biology and may likely unveil targets potentially important to glioblastoma treatment in an effort to improve survival.

Metrics

5 Record Views
9 citations in Scopus

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Web of Science research areas
Medicine, Research & Experimental
Logo image